Mei Zeng
Affiliations: | Dana-Farber Cancer Institute and Harvard Medical School, USA |
Area:
Cancer biology of CDKGoogle:
"Mei Zeng"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zeng M, Xiong Y, Safaee N, et al. (2019) Exploring Targeted Degradation Strategy for Oncogenic KRAS. Cell Chemical Biology |
| Zeng M, Kwiatkowski NP, Zhang T, et al. (2018) Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 7 |
| Zeng M, Kwiatkowski NP, Zhang T, et al. (2018) Author response: Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 Elife |
| Zeng M, Lu J, Li L, et al. (2017) Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chemical Biology |
| Lu J, Harrison RA, Li L, et al. (2017) KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Structure (London, England : 1993) |
| Zeng M, Zhou JN. (2008) Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells Cellular Signalling. 20: 659-665 |